StockData
Caris Life Sciences, Inc. logo

Caris Life Sciences, Inc. (CAI) stock

CAINasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30104% above fair value
$19.94−1.06 (-5.05%)

Close on Nov 17, 2026Market cap $5.63BP/E –Yield –

Caris Life Sciences r&d expenses

Research and development expenses are spending on new products and technology.

Caris Life Sciences's R&D Expenses for the twelve months ending Sep 30, 2026 was $129.36M, up 33.6% year over year. For fiscal 2025 it was $101.58M, down 10.8% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$101.58M-10.8%
FY2024Dec 31, 2024$113.92M-2.5%
FY2023Dec 31, 2023$116.88M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$33.84M+56.5%
Q2 FY2026Jun 30, 2026$32.36M+29.2%
Q1 FY2026Mar 31, 2026$31.32M+35.8%
Q4 FY2025Dec 31, 2025$31.85M+17.5%
Q3 FY2025Sep 30, 2025$21.62M-21.8%
Q2 FY2025Jun 30, 2025$25.05M+1.0%
Q1 FY2025Mar 31, 2025$23.07M–
Q4 FY2024Dec 31, 2024$27.11M–
Q3 FY2024Sep 30, 2024$27.64M–
Q2 FY2024Jun 30, 2024$24.79M–

More Caris Life Sciences figures

See a number that looks wrong?